UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K/A

Commission file number 0-19941

MEDQUIST INC.

New Jersey		22-2531298
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

9009 Carothers Parkway, Suite C-2, Franklin, TN 37067
(Address of principal executive offices)

Title of each class		Name of each exchange on which registered
Common Stock, no par value per share

     Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No þ

     Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

     Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

     Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

     Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer þ		Non-accelerated filer o		Smaller reporting company o
				(Do not check if a smaller reporting company)

     Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

     The aggregate market value of the outstanding common stock held by non-affiliates of the registrant as of June 30, 2010, was $90,519,912. Such aggregate market value was computed by reference to the closing price of the common stock as reported on the Global Market of The NASDAQ Stock Market LLC on June 30, 2010.

     The number of registrant’s shares of common stock, no par value, outstanding as of April 26, 2011 was 37,555,893.

Documents incorporated by reference

     None

 

 

Explanatory Note

          MedQuist Inc. (which may be referred to herein as we, us or the Company) is filing this Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2010 to amend and restate Items 10 through 14 to include the information intended to be incorporated therein by reference to our definitive Proxy Statement with respect to our Annual Meeting of Shareholders for 2011, which information was previously intended to be filed with the Securities and Exchange Commission (SEC) within 120 days following the end of our fiscal year ended December 31, 2010. In addition, in connection with the filing of this Form 10-K/A and pursuant to Rule 12b-15 under the Securities Exchange Act of 1934 (Exchange Act), we are including certain currently dated certifications. The remainder of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (SEC) on March 16, 2011 remains unchanged.

          In March 2011, MedQuist Holdings Inc. (MedQuist Holdings) completed a public exchange offer (Public Exchange) for shares of our common stock which resulted in MedQuist Holdings now beneficially owning approximately 97% of the issued and outstanding shares of our common stock. In accordance with the terms of a Stipulation of Settlement entered into in connection with the settlement of litigation brought by certain of our shareholders in connection with the Public Exchange, and subject to final approval of the settlement by the court presiding over the shareholder litigation, the remaining issued and outstanding shares of our common stock are expected to be exchanged on the same terms as the Public Exchange in a short-form merger by the end of the third quarter of 2011. In connection with this expected short-form merger and to immediately reduce duplicate costs of being a public company, On March 24, 2011, we gave formal written notice to NASDAQ of our intent to voluntarily delist our shares traded under the ticker symbol, MEDQ, and the delisting from NASDAQ became effective on or about April 14, 2011. Shares of our common stock have ceased trading on NASDAQ and are currently trading on the Pink Sheets (as reported by the Pink Sheets LLC) under the symbol “MEDQ.PK”.

PART III

ITEM 10.		DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

Identification of Our Directors

     Our business, property and affairs are managed by, or under the direction of, our board of directors. Each director holds office until his successor is elected and qualified, or until his earlier resignation or removal. Set forth below is the biographical information for each of our directors, including age, business experience for the last five years, any public company directorships held during the last five years, memberships on committees of our board of directors and the date when each director first became a member of our board of directors. We are not aware of any arrangements or understandings between any of the individuals listed below and any other person pursuant to which such individual was or is to be selected as a director, other than any arrangements or understandings with our directors acting solely in their capacities as such.

     Robert Aquilina, 55, has served as chairman of our board of directors since August 2008 and currently serves as chairman of the Compensation Committee. Mr. Aquilina has served as an Executive Partner, a senior operating consultant role, to Siris Capital Group, LLC since March 2011 and to S.A.C. Private Capital Group, LLC (SAC PCG) from 2007 to March 2011. Previously, he served as an Industrial Partner at Ripplewood Holdings LLC (Ripplewood), held the role of Co-Chairman of Flag Telecom Group Ltd. and was a board member of Japan Telecom Inc. Prior to these positions, Mr. Aquilina was a senior operating executive of

AT&T, Inc. with a 21-year career. His last post at AT&T was as Co-President of AT&T Consumer Services and a member of the Chairman’s Operating Group. Previously within AT&T, Mr. Aquilina held a variety of senior positions including President of Europe, Middle East & Africa, Vice Chairman of AT&T Unisource, Vice Chairman of WorldPartners, Chairman of AT&T-UK, and General Manager of Global Data Services. Mr. Aquilina holds an M.B.A. from The University of Chicago and a Bachelors of Engineering degree from The Cooper Union for the Advancement of Science & Art in New York (Cooper Union). Mr. Aquilina has been a Member of Cooper Union’s Board of Trustees since 2000 and is currently chairing Cooper Union’s audit committee. Mr. Aquilina also currently serves as the chairman of the board of directors of MedQuist Holdings Inc., formerly CBay Systems Holdings Ltd. (MedQuist Holdings), which is a public company listed on the NASDAQ Global Market and which currently beneficially owns approximately 97% of us.

     Mr. Aquilina’s extensive executive and senior management experience, and prior board service, enable him to provide leadership and support to the Company in the areas of operations, strategic and financial planning and compensation matters, and render him well-suited to lead our Compensation Committee.

     Frank Baker, 39, has served as a member of our board of directors since August 2008 and currently serves as a member of the Compensation Committee and of the Nominating Committee. Mr. Baker is a Managing Director and co-founder of Siris Capital Group, LLC, which was established in March 2011. Mr. Baker was also a Managing Director and co-founder of SAC PCG from 2007 to March 2011. Prior to establishing SAC PCG in 2007, Mr. Baker was a Managing Director at Ripplewood and RHJ International where he was responsible for making various private equity investments and taking RHJ International public on the Brussels Stock Exchange. He joined Ripplewood’s New York office in 1999 and transferred to Ripplewood Japan, Inc. in 2002. Prior to joining Ripplewood, Mr. Baker spent more than three years in investment banking as an Associate at J.P. Morgan Securities Inc. in the Capital Markets Group and as an Analyst at Goldman Sachs & Co. in the Mergers and Acquisitions Group. Mr. Baker has a B.A. in Economics from the University of Chicago and an M.B.A. from Harvard Business School. Mr. Baker is also currently on the board of directors of MedQuist Holdings.

     Mr. Baker’s vast experience in private equity capital markets, his background in mergers and acquisitions and corporate finance matters, and his entrepreneurial and leadership skills enable him to provide leadership and support to the Company areas of operations, financial planning, and assessing strategic opportunities

     Peter E. Berger, 61, has served as a member of our board of directors since August 2008 and currently serves as a member of the Compensation Committee and as chairman of both the Audit Committee and Nominating Committee. Mr. Berger is a Managing Director and co-founder of Siris Capital Group, LLC, which was established in March 2011. Mr. Berger was also a Managing Director and co-founder of SAC PCG from 2007 to March 2011. From 1995-1998 and 2000-2006, Mr. Berger, a founding member of Ripplewood, served as both a Managing Director of Ripplewood and as a Special Senior Advisor to the board of directors of RHJ International. Prior to joining Ripplewood, Mr. Berger was a senior partner and global head of the Corporate Finance Group at Arthur Andersen & Co., where he began his career in 1974. From 1989-1991, he served as a Managing Director in investment banking at Bear Stearns Companies. From 1999-2000, Mr. Berger was Managing Director and Chief Executive Officer of Mediacom Ventures LLC, a boutique investment advisory firm. He also served as non-executive Chairman of the Board of Kepner-Tregoe, Inc., a management consulting company. Mr. Berger has a B.Sc. from Boston University and an M.B.A. from Columbia University Graduate School of Business. Mr. Berger is also currently on the board of directors of MedQuist Holdings.

     Mr. Berger’s investment banking background, experience in private equity capital markets, deep professional background and experience, and current and previously held senior-executive leadership

positions enable him to provide valuable leadership and support to the Company in the areas of financial and strategic planning.

Governance of the Company

     Our business, property and affairs are managed by, or under the direction of, our board of directors, which currently consists of 3 directors. We currently have 2 vacancies on our board of directors. Our board of directors maintains an Audit Committee, a Nominating Committee and a Compensation Committee, each of which is discussed in detail below.

Independence of Directors

     Our common stock was listed on the Global Market of The NASDAQ Stock Market LLC (NASDAQ) from July 17, 2008 through April 14, 2011. Following the completion of the Public Exchange and our board of directors’ unanimous decision to voluntarily delist from NASDAQ, our former independent directors, Warren E Pinckert II, Andrew E. Vogel, Colin J. O’Brien and John F. Jastrem resigned from our board of directors on March 25, 2011, and former director, Michael Seedman resigned on March 31, 2011. On April 27, 2011, the remaining members of our board of directors set the size of the board at 5 directors.

     Until our delisting from NASDAQ, we qualified as a “controlled company” as defined in Rule 5615(c)(1) of the Marketplace Rules (Marketplace Rules) of NASDAQ because more than 50% of our voting power was controlled by a single shareholder, MedQuist Holdings. As a controlled company, we were exempt from the requirements of Rule 5605(b), (d) and (e) of the Marketplace Rules with respect to our board of directors being comprised of a majority of “independent directors” and the related rules covering the independence of directors serving on the Compensation Committee and the Nominating Committee of our board of directors. The controlled company exemption did not modify the independence requirements of the Audit Committee, which requires three independent directors. Prior to their March 25, 2011 resignations, our Audit Committee consisted of four independent directors (Messrs. Jastrem, O’Brien, Vogel and Pinckert). Our Audit Committee currently consists of three directors (Messrs. Berger (Chair), Aquilina and Baker), none of whom qualify as independent directors.

     As required by the rules of the Securities and Exchange Commission (SEC), our board of directors used the independence requirements of NASDAQ (the Independence Requirements) to assess the independence of each of its members. Our board of directors determined that, prior to their resignations, Messrs. Pinckert, Jastrem, O’Brien and Vogel were “independent” in accordance with the Independence Requirements. In making its determinations, our board of directors did not consider any related party transactions that are not discussed under Item 13, below the heading “Related Party Transactions.”

Committees of our Board of Directors

     Our board of directors maintains the following three standing committees: Audit Committee; Compensation Committee; and Nominating Committee.

Audit Committee

     The Audit Committee oversees our corporate accounting and financial reporting process. The responsibilities of the Audit Committee, which are set forth in a written charter adopted by our board of directors and available on our website at www.medquist.com, include:

•

review and assess the adequacy of the Audit Committee charter at least annually;

	•		evaluate, determine the selection of, and if necessary, the replacement/rotation of, our independent registered public accounting firm;
	•		ensure timely rotation of lead and concurring audit partner of our independent registered public accounting firm;
	•		review our annual audited consolidated financial statements as well as our quarterly consolidated financial statements which are not audited;
	•		review whether interim accounting policies and significant events or changes in accounting estimates were considered by our independent registered public accounting firm to have affected the quality of our financial reporting;
	•		discuss with the independent registered public accounting firm certain matters required to be discussed relating to the conduct of our audits;
	•		discuss with management and the independent registered public accounting firm significant regulatory and financial reporting issues and judgments made in connection with the preparation of our financial statements;
	•		review with management and our independent registered public accounting firm their judgments about the quality of disclosures in our consolidated financial statements;
	•		review and discuss the reports prepared by the internal auditor and management’s responses to such reports;
	•		obtain from our independent registered public accounting firm its recommendation regarding our internal control over financial reporting and review and discuss with the internal auditor and the independent registered public accounting firm management’s report on its assessment of the design and effectiveness of our internal control over financial reporting;
	•		review our major financial risk exposures;
	•		pre-approve all audit and permitted non-audit services and related fees;
	•		establish, update periodically and monitor compliance with our code of business conduct and ethics;
	•		establish and review policies for approving related party transactions between us and our directors, officers or employees; and
	•		adopt procedures for receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters.

     Prior to March 25, 2011, the Audit Committee (or disinterested members of our board of directors) was also responsible for approving or ratifying all related party transactions. If the related party transaction involved compensation of a related party, other than CBay, Inc. or its affiliates, such transaction had to be approved by the Compensation Committee. If the related party transaction involved compensation of CBay, Inc. or its affiliates, such transaction was approved by the Audit Committee. Prior to March 25, 2011, the Audit Committee was composed of Messrs. Pinckert II (Chair), Jastrem, O’Brien

and Vogel. Messrs. Pinckert, Jastrem, O’Brien and Vogel were determined by our board of directors to have met the Independence Requirements for the purposes of serving on the Audit Committee. Our Audit Committee currently consists of three directors (Messrs. Berger (Chair), Aquilina and Baker), none of whom qualify as independent directors. Our board of directors determined that Mr. Pinckert was our “audit committee financial expert” as that term is defined in Item 407(d)(5) of Regulation S-K. Subsequent to the director resignations on March 25, 2011, our board of directors has determined that Mr. Berger is our “audit committee financial expert” as that term is defined in Item 407(d)(5) of Regulation S-K.

Compensation Committee

     While our board of directors is responsible for determining and approving the compensation for our executive officers in its sole discretion, including all individuals whose compensation is set forth in the “Summary Compensation Table” under Item 11, it frequently solicits recommendations from the Compensation Committee regarding the following:

	•		the corporate goals and objectives relevant to the compensation of our President and Chief Executive Officer and our other executive officers;
	•		the performance of these officers in light of those goals and objectives; and
	•		the compensation of these officers based on such evaluations.

     Prior to March 25, 2011, the Compensation Committee was composed of Robert Aquilina (Chair), Frank Baker, Peter Berger and Warren Pinckert. Currently, the Compensation Committee is composed of Messrs. Aquilina, Baker and Berger. The Compensation Committee does not have a written charter.

Nominating Committee

     The responsibilities of the Nominating Committee, which are set forth in a written charter adopted by our board of directors and available on our website at www.medquist.com, includes the selection of potential candidates for our board of directors. The Nominating Committee also makes recommendations to our board of directors concerning the membership of the other board committees and is responsible for developing policies and procedures with regard to the consideration of any director candidates recommended by our shareholders. Prior to March 31, 2011, the Nominating Committee was composed of Peter Berger (Chair), Frank Baker and Michael Seedman. Currently, the Nominating Committee is composed of Messrs. Berger (Chair), Aquilina and Baker.

     Generally, our board of directors seeks diverse members who possess the background, skills and expertise to make a significant contribution to our board of directors, us and our shareholders. The Nominating Committee has adopted a set of procedures to guide it in the identification and evaluation of director nominees. The Nominating Committee supports our view that the continuing service of qualified incumbents promotes stability and continuity in the board room, contributing to our board of directors’ ability to work as a collective body, while giving us the benefit of the familiarity and insight into our affairs that our incumbent directors have accumulated during their tenure. Accordingly, the process of the Nominating Committee for identifying director nominees first considers re-nominating incumbent directors who continue to satisfy the Nominating Committee’s criteria for membership on our board of directors, whom the Nominating Committee believes continue to make important contributions to our board of directors and who consent to continue their service on our board of directors.

     If the Nominating Committee concludes new candidates are appropriate, it will review appropriate biographical information about the proposed candidates considering the following criteria, among others: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly held company; experience in our industry; experience as a board member of another publicly held company; diversity of expertise and experience in substantive matters pertaining to our business relative to other members of our board of directors; and practical and mature business judgment. The Nominating Committee will also consider our board of directors’ overall balance of diversity of perspectives, backgrounds and experiences. In seeking candidates, the Nominating Committee will solicit suggestions from other members of our board of directors and our management and may also engage the services of a professional search firm. The Nominating Committee will discuss and consider the potential candidates and choose which candidates to recommend to our board of directors.

     Candidates proposed by shareholders in accordance with the procedures set forth in our By-Laws will be considered by the Nominating Committee under criteria similar to the evaluation of other candidates, except that the Nominating Committee may consider, as one of the factors in its evaluation of shareholder recommended nominees, the size and duration of the interest in our common stock of the recommending shareholder or shareholder group. The Nominating Committee may also consider the extent to which the recommending shareholder intends to continue holding its interest in us, including, in the case of nominees recommended for election at an annual meeting of shareholders, whether the recommending shareholder intends to continue holding its interest at least through the time of such annual meeting.

Code of Business Conduct and Ethics

     We have adopted a written code of business conduct and ethics which applies to all of our directors, officers and other employees, including our principal executive officer, our principal financial officer and our principal accounting officer. Our code of business conduct and ethics is available on our website at www.medquist.com. Disclosure regarding any amendments to, or waivers from, provisions of the code of business conduct and ethics that apply to our directors, principal executive and financial and accounting officers will be included in a Current Report on Form 8-K within four business days following the date of the amendment or waiver, unless web site posting of such amendments or waivers is then permitted by the rules of NASDAQ.

Section 16(a) Beneficial Ownership Reporting Compliance

     Section 16(a) of the Exchange Act requires that each of our executive officers, directors and persons who beneficially own more than 10% of our common stock file with the SEC reports of ownership and changes in their ownership of our common stock. Our executive officers and directors and beneficial owners of greater than 10% of our common stock are required by SEC regulations to provide us with copies of all Section 16(a) forms that they file. Based solely on our review of the copies of such forms furnished to us, we believe that for the year ended December 31, 2010, all of our executive officers, directors and persons owning greater than 10% of our common stock complied with all Section 16(a) filing requirements applicable to them.

Executive Officers of the Company

     Peter Masanotti, 56, has served as our Chief Executive Officer since September 2008 and as our President since November 2008. On March 16, 2011, Mr. Masanotti was also appointed to the positions of President and Chief Executive Officer of MedQuist Holdings. Prior to joining us, Mr. Masanotti was managing director and global head of Business Process Sourcing at Deutsche Bank since May 2007,

where he was responsible for offshore and onshore labor productivity and efficiency for the investment banking platform. From July 2005 through May 2007, Mr. Masanotti was the Chief Operating Officer and Executive Vice President of OfficeTiger LLC, a judgment-based business outsourcing firm which services major investment banks and Fortune 500 companies. From December 2001 to May 2005, Mr. Masanotti served as Chief Operating Officer of Geller & Company, a privately held finance and accounting outsourcing firm. Mr. Masanotti has a B.A. in economics from the University of Connecticut-Storrs. He is also a graduate of the Temple University School of Law.

     Anthony D. James, 44, has served as our Chief Financial Officer since November 2010 and as our Co-Chief Operating Officer since June 2010. On March 16, 2011, Mr. James was also appointed to the position of Chief Financial Officer of MedQuist Holdings. Mr. James served as the Chief Operating Officer for Spheris Inc., a global outsource provider of clinical documentation technology and services (Spheris), from 2006 until April 2010, when we and CBay Inc., purchased substantially all of the assets of Spheris. Prior to that, Mr. James served as the Chief Financial Officer for Spheris from 2001 to 2006. James joined Spheris in November 1999 as the company’s Controller. Prior to Spheris, Mr. James held a number of finance and accounting positions over a seven year tenure with Mariner Post-Acute Network. Additionally, he worked for two years in public accounting for Schoenauer, Musser & Co. Mr. James is a certified public accountant and has a B.A. in Accounting from the University of Northern Iowa.

     Michael F. Clark, 49, has served as our Co-Chief Operating Officer since June 2010 and prior to that he served as our Chief Operating Officer from June 2009 to June 2010. Mr. Clark previously served as our Senior Vice President of Operations from February 2005 to June 2009. Mr. Clark joined us in 1998 through our acquisition of MRC. From November 2003 until February 2005, Mr. Clark served as our Senior Vice President of Operations for our Western Division. From May 2002 until November 2003, Mr. Clark served as our Vice President of Operations for our Southwest Division and from January 1998 until July 2000, he served as Region Vice President for the Southeast. From May 2001 until May 2002, Mr. Clark served as Chief Operating Officer for eScribe, a transcription service provider. While at MRC, Mr. Clark served as Vice President, Marketing and Corporate Services. Mr. Clark has a B.S. in Marketing and International Business from Miami University in Oxford, Ohio and an M.B.A. from the University of Miami in Coral Gables, Florida.

     Mark R. Sullivan, 39, serves as our General Counsel, Chief Compliance Officer and Secretary. Mr. Sullivan was appointed as General Counsel in September 2006, Chief Compliance Officer in July 2006 and Secretary in January 2005. On March 16, 2011, Mr. Sullivan was also appointed to the position of General Counsel, Chief Compliance Officer and Secretary of MedQuist Holdings. From August 2004 until September 2006, Mr. Sullivan served as our Acting General Counsel. Between March 2003 and August 2004, Mr. Sullivan served as our Associate General Counsel and Assistant Secretary. Prior to joining us, Mr. Sullivan was in private practice with Pepper Hamilton LLP from January 2000 until March 2003, and Drinker Biddle & Reath LLP from August 1998 to January 2000. Mr. Sullivan has a B.A. in History from the University of Pennsylvania and is a graduate of the Rutgers University School of Law.

     Kevin Piltz, 52, has served as our Chief Information Officer since June 2009. Prior to joining us, Mr. Piltz was the Chief Information Officer for Geller & Company, a privately held finance and accounting outsourcing firm, from 2002 to 2009. From 1998 to 2002, Mr. Piltz was the Chief Information Officer of ITDS, a provider of information solutions to the communications and IP industry. Mr. Piltz has a B.S. in Business from the Ball State University of Indiana.

     We are not aware of any arrangements or understandings between any of the individuals listed above and any other person pursuant to which he or she was or is to be selected as an officer, other than any arrangements or understandings with our officers acting solely in their capacities as such.

ITEM 11.		EXECUTIVE COMPENSATION.

Compensation Discussion and Analysis

Compensation Philosophy

     We provide our executive officers, including our President and Chief Executive Officer (Mr. Masanotti), with incentives tied to the achievement of our corporate objectives.

     During the past few years, in making executive hiring and compensation decisions, we considered the risks associated with our ongoing litigation and governmental investigation matters, the change in our majority shareholder, and our board or directors’ decision not to provide traditional equity-based long term incentives on an ongoing basis. During the past few years, we experienced a significant turnover in our senior management. In light of all of these challenges, our board of directors established a total compensation philosophy and structure designed to accomplish the following objectives:

	•		attract, retain and motivate executives who can thrive in a competitive environment of continuous change and who can achieve positive business results in light of the challenges that we have faced and continue to face;
	•		provide our executives with a total compensation package that recognizes individual contributions, as well as overall business results; and
	•		promote and reward the achievement of objectives that our board of directors and management believe will lead to long-term growth in shareholder value, including the resolution of our ongoing litigation and governmental investigation matters.

     To achieve these objectives, we intend to maintain compensation arrangements that tie a substantial portion of our executive officers’ overall compensation to the achievement of key strategic, operational and financial goals.

Setting Executive Officer Compensation

Board of Directors, Compensation Committee and Management

     While our board of directors is responsible for determining and approving the compensation of our executive officers in its sole discretion, it frequently solicits recommendations from the Compensation Committee regarding:

	•		the corporate and individual goals and objectives relevant to the compensation of our executive officers;
	•		the evaluation of our corporate performance and the performance of our executive officers in light of such goals and objectives; and
	•		the compensation of our executive officers based on such evaluations.

     Our President and Chief Executive Officer, our head of Human Resources and the Compensation Committee together review the performance of our executive officers, other than Mr. Masanotti, provide our board of directors with the results of the review and make recommendations to our board of directors for final approval with respect to the compensation of our executive officers. Our board of directors

currently is, and will continue to be, responsible for setting the compensation of Mr. Masanotti (currently determined pursuant to an employment agreement between us and Mr. Masanotti) and evaluating his performance based on corporate goals and objectives. The terms of the agreement with Mr. Masanotti were negotiated and approved by our board of directors and are described below under the caption “Compensation of our President and Chief Executive Officer.”

     Our executive officers do not play a role in their own compensation determination, other than discussing individual performance objectives with our President and Chief Executive Officer.

     Analysis of Market Compensation Data

     In 2009, we engaged Mercer, a compensation consulting firm that is a wholly-owned subsidiary of Marsh & McLennan Companies, Inc. (Mercer), to perform benchmarking analysis for executive total compensation for our top 6 executive positions (other than the Chief Executive Officer position):

Chief Financial Officer
Chief Technology Officer
General Counsel & Chief Compliance Officer
Senior Vice President of Operations
Senior Vice President of Sales & Marketing
Vice President of Human Resources

     In addition we requested that Mercer provide recommendations for a long term incentive plan, and any appropriate revisions to our management incentive plan. The Mercer benchmarking analysis included publicly available information for the following health care IT and business process outsourcing companies (collectively, Peer Companies):

•		Transcend Services, Inc.		•		MedAssets, Inc.
•		Nuance Communications, Inc.		•		ICT Group, Inc.
•		Spheris Inc.		•		Comforce Corporation
•		QuadraMed Corp.		•		Exl Service Holdings, Inc.
•		Eclipsys Corporation		•		Gevity HR Inc.
•		Allscripts-Misys Healthcare Solutions, Inc.

     Mercer also utilized published compensation survey data, calibrated for our revenues, to get a broader industry perspective on market pay levels for functionally comparable positions.

     Mercer’s report concluded that, with respect to the six identified senior executive positions, we were within 15% of (i) the average base salary (ii) target incentive compensation, and (ii) combined base salary and target incentive levels for similarly situated executives based upon the analysis of the publicly available information for the Peer Companies and published compensation survey data. We have not assessed, and the scope of Mercer’s engagement did not include an assessment of, where our actual 2009 management incentive plan payments fell in comparison to the publicly available information for the Peer Companies or published compensation survey data.

     When Messrs. Piltz and Golio were subsequently hired in 2009, their target incentive level (50% of base salary) fell within 15% of target incentive levels for similarly situated executives based upon the analysis of the Peer Companies and published compensation survey data. Our Compensation Committee and board of directors decided not to make any changes to the target incentive levels for our named executive officers (other than our Chief Executive Officer) as a result of Mercer’s analysis

because they believed that our target incentive levels are in line with similarly situated executives at the Peer Companies.

     The target incentive level for our Chief Executive Officer, Mr. Masanotti (up to 140% of base salary), was negotiated between him and our board of directors.

Elements of Compensation

     Our executive compensation program utilizes four primary elements to accomplish the objectives described above:

	•		base salary;
	•		annual cash incentives linked to corporate and individual performance;
	•		long-term incentives; and
	•		benefits and perquisites.

     We believe that we can meet the objectives of our executive compensation program by achieving a balance among these four elements that is competitive with our industry peers and creates appropriate incentives for our executive officers. Actual compensation levels are a function of both corporate and individual performance as described under each compensation element below. In making compensation determinations, the Compensation Committee and our board of directors consider the competitiveness of compensation both in terms of individual pay elements and the aggregate compensation package.

Base Salary

     We provide our executive officers with base salary in the form of fixed cash compensation to compensate them for services rendered during the fiscal year. Consistent with our compensation philosophy, our board of directors believes that the current base salaries of our executive officers are at levels competitive with Peer Companies with additional consideration given to the challenges we have and continue to face.

     The base salary of our executive officers is reviewed for adjustment annually by our board of directors. Generally, in making a determination of whether to make base salary adjustments, our board of directors considers the following factors:

	•		our success in meeting our strategic operational and financial goals;
	•		our President and Chief Executive Officer’s assessment of such executive officer’s individual performance;
	•		length of service to us of such executive officer;
	•		changes in scope of responsibilities of such executive officer; and
	•		the base salaries of executive officers at Peer Companies possessing similar job titles.

     In addition, our board of directors considers internal equity within our organization and, when reviewing the base salaries of our executive officers, their current aggregate compensation.

2010 Base Salaries

     After considering the salary adjustment factors detailed above, our board of directors determined that no merit based salary increases would be made in 2010 for our named executive officers, except for those named executive officers whose individual performance was at an exceptional level in 2009. Our board of directors, after (i) assessing the performance of our Chief Executive Officer and (ii) reviewing the assessment by our Chief Executive Officer of each of our named executive officers (other than the Chief Executive Officer), determined that there would be no changes to the base salaries of the named executive officers in 2010.

     The 2010 base salaries of our executive officers were as follows:

		2010 Annual Base
Name		Salary Rate ($)
Peter Masanotti			500,000
Anthony D. James(1)			300,000
Kevin Piltz (2)			280,000
Michael Clark			275,000
Dominick Golio (3)			275,000
Mark R. Sullivan			237,930

2011 Base Salaries

     No base salary adjustments for our executive officers have been made for 2011.

Annual Cash Incentive

     We believe that performance-based cash incentives play an essential role to motivate our executive officers to achieve defined annual goals. The objectives of our annual management incentive plans are to:

•

align the interests of executives and senior management with our strategic plan and critical performance goals;

	•		motivate and reward achievement of specific, measurable annual individual and corporate performance objectives;
	•		provide payouts commensurate with our performance;
	•		provide competitive total compensation opportunities; and
	•		enable us to attract, motivate and retain talented executive management.

2010 Management Incentive Plan

     The Compensation Committee recommended, and our board of directors approved, our 2010 Management Incentive Plan (2010 Plan) in January 2010. The exact performance measures were not established until September 2010, following the acquisition of Spheris in the fiscal year.

     Participation; Eligibility. Select key management level employees were eligible to participate in our 2010 Plan, including each of the executive officers identified above. Other criteria for participation and eligibility to receive an incentive reward under the 2010 Plan include the following:

	•		a participant must receive a performance rating of “solid performer” or better for 2010 to receive an incentive award; and
	•		a participant must have been an active employee as of March 15, 2011 to receive an incentive award.

     Incentive Targets. Each of our executive officers was eligible to receive a target annual cash incentive award expressed as a percentage of his or her base salary for 2010 (Target Incentive). The table below entitled “Grants of Plan-Based Awards” (and, specifically, the information under the caption “Estimated Possible Payouts Under Non-Equity Incentive Plan Awards”) illustrates the threshold, target and maximum amounts of cash incentives that were potentially payable to our named executive officers with respect to 2010 performance under the 2010 Plan.

     Performance Measures under the 2010 Plan. Payment of incentive awards under the 2010 Plan was based on a combination of corporate objectives, and an assessment of individual performance toward achievement of those corporate objectives as a way to communicate our expectations and to maintain and unify our executives’ focus on our key strategic objectives, as well as to measure performance. The Annualized Net Sales Volume and Adjusted EBITDA targets established exclusively for the 2010 Plan and the assessment of each named executive officer’s individual performance toward achieving those corporate objectives is based on certain internal normal operating financial goals set in connection with our board of directors’ consideration and approval of our annual operating plan for 2010. The performance measures for the 2010 Plan and the relative weighting of the performance measures were:

	•		50% of a participant’s target incentive could be paid upon a 2010 Adjusted EBITDA target established exclusively for the 2010 Plan. 100% of the 2010 Adjusted EBITDA target under the 2010 Plan must be achieved for any incentive under the 2010 Plan to be awarded. There is no maximum payout limit under the Adjusted EBITDA portion of the 2010 Plan;
	•		25% of a participant’s target incentive could be paid upon a 2010 Annualized Net Sales Volume target. Before the Annualized Net Sales Volume Target is determined eligible

			for payout, we must achieve 100% of the EBITDA target. In addition, we must achieve 95% of 2010 Annualized Net Sales Volume Target for any portion of this component to be awarded; and
	•		25% of a participant’s target incentive could be paid the assessment of such named executive officer’s 2010 individual performance toward achieving the Adjusted EBITDA and Annualized Net Sales Volume targets established exclusively for the 2010 Plan.

     The 2010 base salaries and the 2010 Plan target incentives (as a percentage of base salary for each of our named executive officers) were as follows:

		2010 Annual Base				2010 Plan Target Incentive
Name		Salary Rate ($)				As percentage of base salary
Peter Masanotti			500,000			up to 140		%
Anthony D. James(1)			300,000				50	%
Kevin Piltz			280,000				50	%
Dominick Golio(2)			275,000				50	%
Michael Clark			275,000				45	%
Mark R. Sullivan			237,930				45	%

     The Adjusted EBITDA target established exclusively for the 2010 Plan was $72.3 million and we achieved an Adjusted EBITDA under the 2010 Plan equal to $81.8 million, which was 113% of such Adjusted EBITDA target established exclusively for the 2010 Plan. We achieved 100% of the Annualized Net Sales Volume target established exclusively for the 2010 Plan.

     Adjusted EBITDA is a non-GAAP financial measure. Our board of directors calculated the Adjusted EBITDA achievement exclusively for the 2010 Plan as standard EBITDA, adjusted for any item of expense or income that was non-recurring and unrelated to normal operating activities.

     Based upon the levels of Adjusted EBITDA and Annualized Net sales Volume Targets established exclusively for the 2010 Plan that were achieved, each 2010 Plan participant (other than Mr. Masanotti) received a payout equal to 78% of his or her 2010 Plan incentive target. The payout was based upon (i) the Annualized Net Sales Volume Targets established exclusively for the 2010 Plan (100% achievement, resulting in 25% of the target incentive awarded for this component) and (ii) the Adjusted EBITDA level as calculated under the 2009 Plan (113% achievement, resulting in 53% of the target incentive awarded for this component). These two components combined to a total award of 78% of the target incentive. Our board of directors, in its discretion, determined that the individual performance of each named executive officer in 2010, other than Messrs. Massanotti and Golio, warranted payment of an additional 24.7% of each named executive officer’s target incentive. Accordingly, Messrs. James, Clark, Sullivan and Piltz received 102.3% of their Target Incentive under the 2010 Plan. Our board of directors, in its discretion, determined that the individual performance of Mr. Golio, warranted payment of an additional 25% of his target incentive. Accordingly, Mr. Golio received 103% of his Target Incentive under the 2010 Plan. In order to be more aligned with the rest of the senior management team, our board of directors determined that Mr. Masanotti should be paid 78.6% of his 2010 Plan target incentive amount (which equals 110% of his salary for 2010). The incentive awards discussed above resulted in the following payment calculations to our named executive officers under the 2010 Plan which are scheduled to be made on or about May 3, 2011:

Executive		Incentive Payment
Peter Masanotti		$	550,000
Dominick Golio		$	141,625
Anthony D. James		$	105,533
Mark R. Sullivan		$	109,568
Michael Clark		$	126,640
Kevin Piltz		$	143,269

2011 Management Incentive Plan

     A 2011 Management Incentive Plan (the “2011 Plan”) has not yet been approved by our board of directors. It is anticipated that the terms of the 2011 Plan will be substantially similar to the terms of the 2010 Plan, that individual performance objectives for the 2011 Plan will be set in the same manner as they were set in the 2010 Plan and that the financial performance targets under the 2011 Plan and the individual performance objectives for each executive officer under the 2011 Plan will be based on certain internal financial goals set in connection with our board of directors’ consideration and approval of our annual operating plan for 2011.

Long-Term Incentives

Equity-Based Incentives

     On September 30, 2008 (Grant Date), we made a stock option grant (Original Stock Option Grant) to Mr. Masanotti to purchase up to 295,749 shares of our common stock at the fair market value of our common stock as of September 30, 2008, which was $4.85 per share, with the options expiring on September 30, 2018. The number of shares that Mr. Masanotti was granted an option to purchase was provided for in Mr. Masanotti’s Employment Agreement with us dated September 3, 2008 (Masanotti Employment Agreement). On March 2, 2009, we entered into an Amended and Restated Stock Option Agreement with Mr. Masanotti (Amended Masanotti Option Agreement), to (i) amend the exercise price of the Original Stock Option Grant and (ii) to provide that if Mr. Masanotti’s employment by us or one of our subsidiaries is terminated by us for “cause” as defined in the Masanotti Employment Agreement, the option will terminate immediately in full whether or not vested or exercisable. The Amended Masanotti Option Agreement provides, among other things, that:

	•		the exercise price shall be equal to the higher of (i) the fair market value of the Company’s common stock as of the Grant Date or (ii) $8.25. The fair market value of our common stock (as reported by NASDAQ) on the Grant Date was $4.85, accordingly the exercise price was set at $8.25;
	•		one-third (1/3) of the shares subject to the option vest on the first anniversary of the Grant Date and, thereafter, one-sixth (1/6) of the shares subject to the option vest on each of the following: the date that is six months after the first anniversary of the Grant Date, the second anniversary of the Grant Date, the date that is six months after the second anniversary of the grant date, and the third anniversary of the Grant Date;
	•		upon the occurrence of a “change in control” or our termination of Mr. Masanotti’s employment by us “without cause” or by him for “good reason” (each, as defined in the Masanotti Employment Agreement), the options shall become immediately exercisable, to the extent not already vested; and
	•		in the event of termination of Mr. Masanotti’s employment for any reason other than “without cause” by us, or for “good reason” by him, any of the unvested options shall be immediately forfeited.

     On December 31, 2010, in accordance with anti-dilution terms of the Amended Masanotti Option Agreement, the Compensation Committee approved an adjustment to the exercise price of Mr. Masanotti’s options from $8.25 per share to $2.22 per share to account for the payment of extraordinary cash dividends of $1.33 per share in September 2009 and $4.70 per share in October 2010 to our shareholders.

     In June 2004, our board of directors decided not to provide traditional equity-based long term incentives until we became current in our reporting obligations under the Exchange Act. Accordingly, from June 2004 until we became current in our reporting obligations under the Exchange Act in 2007, we suspended the granting of any stock options. Messrs. Sullivan and Clark received grants of stock options as part of their compensation prior to the decision by our board of directors on June 2004 to not provide traditional equity-based long term incentives. Such grants, to the extent they have not expired, are shown below in the under the heading “Outstanding Equity Awards at Fiscal Year-End.”

2009 Long Term Incentive Plan

     In August 2009 our board of directors adopted a long-term incentive plan (LTIP) for certain members of our senior management team. The LTIP is administered by the Compensation Committee and is designed to encourage and reward the creation of long-term equity value by certain members of our senior management team. Effective as of January 1, 2009, certain executives and key employees who will be selected by the Compensation Committee (each, a participant) became eligible to participate in the LTIP.

     Cash payments pursuant to the LTIP will be made in three equal annual installments during the three years following the expiration of the LTIP’s term (December 31, 2011). The aggregate value available for distribution under the LTIP will be based on the growth of the Company’s equity value between December 31, 2008 and December 31, 2011 (the LTIP Aggregate Pool). The “equity value” of the Company under the LTIP is as an amount equal to, as determined by our Compensation Committee in December 2010 and as of the applicable date of calculation, the latest 12-month EBITDA times a multiple of 5x, less all short- and long-term debt of the Company, plus all cash of the Company with the aggregate amounts of the September 2009 extraordinary cash dividend ($49,949,000) and the October 2010 extraordinary cash dividend ($176,512,697) added back to cash. Our Compensation Committee also may make certain adjustments to the calculation of the equity value of the Company in accordance with the terms of the LTIP.

     Each participant will receive payments out of the LTIP Aggregate Pool in accordance with the number of points such participant earns over the term of the LTIP. Points will be awarded based on Company performance and individual achievement, as well as for hiring and retention purposes. Points can be awarded at any time during the LTIP’s term, but will generally be awarded annually. An aggregate of 600 points (correlating to the 6% of total equity value represented by the LTIP Aggregate Pool) are available for awards over the LTIP’s term. At the end of the LTIP’s term, each point will be converted into the right to receive a cash amount equal to 0.01% of the LTIP Aggregate Pool. The award of points is at the sole discretion of the Compensation Committee.

     Actual payments that may be made under the LTIP cannot be currently estimated because they depend on the number of points awarded to each participant and the value of the LTIP Aggregate Pool, which will only be determinable upon completion of the Company’s audited financial statements for fiscal year 2011.

     The LTIP and payments thereunder may be accelerated upon a change of control, or decelerated in the event that the Company’s equity value diminishes during any fiscal year in which payments are otherwise scheduled to be made pursuant to the terms of the LTIP.

     During the third quarter of 2010, our Compensation Committee issued the following awards to our named executive officers under the Long Term Incentive Plan:

Participant		Total Point Awards in 2010
Michael F. Clark			63.3
Kevin Piltz			40.0
Anthony D. James			21.1
Dominick Golio(1)			20.0
Mark R. Sullivan			14.0

Severance Agreements

Employment Agreement Severance

     The severance arrangements applicable to Messrs. Masanotti, Piltz, Sullivan and Clark are set forth in each of their respective employment agreements, as discussed in detail below under the heading “Potential Payments Upon Termination or Change in Control.” Our former Chief Financial Officer, Mr. Golio, is no longer employed by us. The terms of his separation from us, including severance payments, are set forth in the agreement we entered into with him that is discussed in detail below under the heading “Separation Arrangements with Former Executive Officer.”

Benefits and Perquisites

Benefits

     We maintain broad-based benefits that are provided to all full-time employees, including health and dental insurance, life and disability insurance and our 401(k) plan. Certain of these benefits require employees to pay a portion of the premium. These benefits are offered to our executive officers on the same basis as all other employees, except that we provide, and pay the premiums for, additional long term disability and life insurance coverage for such executive officers.

Perquisites or Other Personal Benefits.

     Our executive officers are entitled to few perquisites or other personal benefits that are not otherwise available to all of our employees. In 2010, we provided premium payments for additional long term disability and life insurance coverage to our executive officers.

     Additional compensation provided to Messrs. Masanotti, Golio (our former Chief Financial Officer) and Piltz (including certain travel and lodging expenses) are detailed below under the heading “Summary Compensation Table.”

     These perquisites or other personal benefits represent a relatively modest portion of each executive officer’s compensation. We do not anticipate any significant changes to the perquisites or other personal benefits levels of our executive officers for 2011.

Compensation of our President and Chief Executive Officer

     Compensation of Mr. Masanotti, our President and Chief Executive Officer

     In connection with his appointment as our Chief Executive Officer, we entered into an employment agreement with Mr. Masanotti, dated as of September 3, 2008 (Masanotti Employment Agreement), pursuant to which Mr. Masanotti will serve as our Chief Executive Officer through December 31, 2011. Our board of directors is responsible for monitoring and reviewing the performance of Mr. Masanotti on an ongoing basis.

     In structuring Mr. Masanotti’s compensation, our board of directors considered the importance of motivating a new Chief Executive Officer to make a long-term commitment to us and to consistently grow our business. Based on these and other considerations, our board of directors approved compensation for Mr. Masanotti comprised of a sign-on bonus, base salary, cash bonus and equity incentives.

     In addition, Mr. Masanotti will receive an annual base salary of $500,000 and may receive an annual bonus award based upon the achievement of target performance objectives established by our board of directors, equal to up to 140% of his base salary, or $700,000 based upon his current base salary. The Masanotti Employment Agreement provides that Mr. Masanotti’s target performance objectives will be established by our board of directors within the first three months of each fiscal year during the term of his employment agreement. Our board of directors believes that the target performance objectives to be established, although not guaranteed, will be capable of being achieved if Mr. Masanotti meets or exceeds his individual objectives, if we perform according to our operating plans and if the assumptions in our operating plans prove correct.

     Pursuant to the terms of the Masanotti Employment Agreement, Mr. Masanotti received a stock option grant from us to purchase up to 295,749 shares of our common stock. See “Long-Term Incentives — Equity-Based Incentives” above, for additional information regarding the stock option grant to Mr. Masanotti.

Tax and Accounting Considerations Affecting Executive Compensation

     We structure our compensation program in a manner that is consistent with our compensation philosophy and objectives. However, while it is the Compensation Committee and our board of directors’ general intention to design the components of our executive compensation program in a manner that is tax efficient for both us and our executives, there can be no assurance that the Compensation Committee or our board of directors will always approve compensation that is tax advantageous for us.

     We endeavor to design our equity incentive awards conventionally, so that they are accounted for under standards governing equity-based arrangements and, more specifically, so that they are afforded fixed treatment under those standards.

Compensation Committee Report

     We, the Compensation Committee of the board of directors of MedQuist Inc., have reviewed and discussed the “Compensation Discussion and Analysis” set forth above with management and, based on such review and discussions, we recommend to the board of directors that the “Compensation Discussion and Analysis” set forth above be included in this Annual Report on Form 10-K.

Compensation Committee of the Board of Directors:

Robert Aquilina, Chairman
Frank Baker
Peter E. Berger

The preceding Report of the Compensation Committee shall not be deemed to be incorporated by reference into any filing made by us under the Securities Act or the Exchange Act, notwithstanding any general statement contained in any such filing incorporating this report by reference, except to the extent we incorporate such report by specific reference.

Summary Compensation Table 2010

     The following table sets forth, for the year ended December 31, 2010, summary information concerning compensation of (i) all individuals who served as our Chief Executive Officer during the fiscal year ended December 31, 2010; (ii) all individuals who served as our Chief Financial Officer during the fiscal year ended December 31, 2010; and (iii) three of our most highly compensated executive officers during the fiscal year ended December 31, 2010, other than those who served as our Chief Executive Officer and Chief Financial Officer, who were serving as executive officers as of December 31, 2010; (collectively, the named executive officers).

																		Non-Equity
														Option				Incentive Plan				All Other
Name and						Salary				Bonus(1)				Awards(2)				Compensation(3)				Compensation(4)				Total
Principal Position		Year				($)				($)				($)				($)				($)				($)
Peter Masanotti,			2010				500,000				—								550,000				7,977				1,057,977
President and Chief			2009				500,000				—				—				700,000				7,258				1,207,258
Executive Officer (5)			2008				125,000				—				583,099				—				3,118				711,217
Dominick Golio,			2010				275,000				—				—				141,625				12,475				429,100
Senior Vice President and Chief Financial Officer(6)			2009				186,506				—				—				137,500				9,321				333,327
Anthony D. James			2010				197,000				40,000				—				105,533				906				343,439
Chief Financial Officer and Co-Chief Operating Officer(7)
Mark R. Sullivan ,			2010				237,930				—				—				109,568				1,416				348,914
General Counsel,			2009				237,930				—				—				108,193				1,605				347,728
Chief Compliance			2008				235,909				155,926				—				107,069				1,836				500,740
Officer and Secretary
Michael Clark,			2010				275,000				—				—				126,640				1,600				403,240
Chief Operating			2009				258,979				—				—				118,929				1,687				379,595
Officer; and Senior			2008				229,781				151,876				—				119,469				1,808				502,934
Vice President of Operations
Kevin Piltz,			2010				280,000				—				—				143,269				2,500				425,769
Senior Vice President and			2009				163,333				—				—				140,000				2,547				305,880
Chief Information Officer(8)

						Long Term
		Group Life				Disability
		Insurance				Insurance
		Premium				Premium				Other
		Cost				Cost				Perquisites(a)
Name		($)				($)				($)				Total
Peter Masanotti			1,225				1,254				5,498				7,977
Anthony D. James			381				525				—				906
Dominick Golio			674				926				10,875				12,475
Mark R. Sullivan			583				833				—				1,416
Michael Clark			674				926				—				1,600
Kevin Piltz			686				933				881				2,500

Grants of Plan-Based Awards 2010

     The following table sets forth each grant of an award made to each named executive officer for the year ended December 31, 2010.

										Estimated Possible Payouts Under
										Non-Equity Incentive Plan Awards(2)
		Grant				Point				Threshold				Target				Maximum
Name		Date(1)				Awards(#)(1)				($)(3)				($)				($)(4)
Peter Masanotti			—				—				393,750				525,000				700,000
Anthony D. James		July 22, 2010					21.1				51,562				103,125				—
Dominick Golio(5)		July 22, 2010					20.0				68,750				137,500				—
											—								—
Mark R. Sullivan		July 22, 2010					14.0				53,535				107,069				—
Michael Clark		July 22, 2010					63.3				58,836				117,672				—
Kevin Piltz		July 22, 2010					40.0				75,000				140,000				—

Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table

     We have or had written employment agreements with each of our named executive officers that provide or provided for the payment of base salary and for each named executive officer’s participation in our bonus programs and employee benefit plans.

     As discussed in “Long-Term Incentives – Equity-Based Incentives” above, on September 30, 2008 (Grant Date), we made a stock option grant (Original Stock Option Grant) to Mr. Masanotti, to purchase up to 295,749 shares of our common stock at the fair market value of the our common stock as of September 30, 2008, which was $4.85 per share, with the options expiring on September 30, 2018. On

March 2, 2009, we entered into an Amended and Restated Stock Option Agreement with Mr. Masanotti (Amended Masanotti Option Agreement), to, among other things, amend the exercise price of the Original Stock Option Grant. The Amended Masanotti Option Agreement provides, among other things, that the option price is equal to the higher of (i) the fair market value of the Company’s common stock as of the Grant Date or (ii) $8.25. The fair market value of our common stock (as reported by NASDAQ) on the Grant Date was $4.85, accordingly the exercise price was set at $8.25. On December 31, 2010, in accordance with anti-dilution terms of the Amended Masanotti Option Agreement, the Compensation Committee approved an adjustment to the exercise price of Mr. Masanotti’s options from $8.25 per share to $2.22 per share to account for the payment of extraordinary cash dividends of $1.33 per share in September 2009 and $4.70 per share in October 2010 to our shareholders.

     In addition, each agreement specifies payments and benefits that would be due to such named executive officer upon the termination of his employment with us. See “Potential Payments Upon Termination or Change-In-Control” below, for additional information regarding amounts payable upon termination to each of our named executive officers.

Outstanding Equity Awards at 2010 Fiscal Year-End

     The following table sets forth all outstanding equity awards held by each of our named executive officers as of December 31, 2010.

		Number of Securities Underlying
		Unexercised Options (#)
										Option Exercise				Option Expiration
Name		Exercisable				Unexercisable				Price				Date
Peter Masanotti			197,166	(4)			98,583	(4)		$	2.22	(5)		September 30, 2018
Anthony D. James			—				—				—				—
Mark R. Sullivan			2,500	(1)			—			$	16.21			March 17, 2013
			20,000	(2)						$	27.89			May 29, 2012
Michael Clark			9,000	(3)			—			$	17.45			February 4, 2013
Dominick Golio			—				—				—				—
Kevin Piltz			—				—				—				—

Option Exercises and Stock Vested During Last Fiscal Year

     There were no option exercises by any of our named executive officers during the year ended December 31, 2010.

Pension Benefits

     None of our named executive officers participate in or have account balances in qualified or non-qualified defined benefit plans that provide for payments or other benefits at or in connection with retirement sponsored by us.

Potential Payments Upon Termination or Change-In-Control

     The following is a discussion of payments and benefits that would be due to each of our named executive officers, upon the termination of his or her employment with us. The amounts in the table below assume that each termination was effective as of December 31, 2010 and are merely illustrative of the impact of a hypothetical termination of each executive’s employment. The amounts to be payable upon an actual termination of employment can only be determined at the time of such termination based on the facts and circumstances then prevailing.

Severance Payments

Mr. Masanotti

     Under the terms of our employment agreement with Mr. Masanotti, he will be entitled to the continuation of his then current base salary for a period of 12 months in the event that:

	•		his employment is terminated by us “without cause” (as defined below),
	•		he resigns for “good reason” (as defined below), or
	•		we elect not to extend the term of Mr. Masanotti’s employment beyond the initial term or any of the automatic one-year extensions following the initial term of the employment agreement..

     In order to receive the severance payments described herein, Mr. Masanotti is required to execute and deliver a general release of claims against us.

     As used in Mr. Masanotti’s employment agreement with us, the term “cause” means the occurrence of any of the following: (1) his failure to substantially perform his duties set forth in the employment agreement (other than as a result of total or partial incapacity due to physical or mental illness) for a period of 15 days following written notice by us to him of such failure, (2) dishonesty in the performance of his duties hereunder, (3) his conviction of, or plea of nolo contendere to a crime constituting (x) a felony under the laws of the United States or any state thereof or (y) a misdemeanor involving moral turpitude, (4) his willful malfeasance or willful misconduct in connection with his duties set forth in the employment agreement or any willful act or omission which is demonstrably injurious to our financial condition or business reputation or any of our subsidiaries or affiliates or (5) his breach of the provisions in the employment agreement relating to non-competition, confidentiality and our intellectual property.

     As used in Mr. Masanotti’s employment agreement with us, the term “good reason” means (1) the failure of us to pay or cause to be paid his base salary or annual bonus, when due pursuant to the terms of the employment agreement, (2) any reduction in his base salary or annual bonus opportunity set forth in the employment agreement, (3) any substantial and sustained diminution in his authority, title, reporting relationship or responsibilities from those described in the employment agreement, or (4) our material breach of the employment agreement; provided that any of the foregoing events shall constitute good reason only if we fail to cure such event within 30 days after receipt from Mr. Masanotti of written notice of the event which constitutes good reason; provided, further, that “good reason” shall cease to exist for an event on the 60^th day following the later of its occurrence or Mr. Masanotti’s knowledge thereof, unless he has given us written notice thereof prior to such date.

     Mr. Masanotti is bound by certain non-competition and non-solicitation covenants which extend for a period of 12 months following termination of his employment for any reason.

Messrs. James, Piltz, Sullivan and Clark

     Under the terms of his employment agreement, Mr. James will be entitled to continuation of his then current base salary for a period of 12 months in the event he is terminated “without cause” (as defined below), or if her terminates his employment for “good reason” (as defined below). As used in Mr. James’ employment agreement with us, the term “good reason” means (i) any substantial and sustained diminution of his duties, including but not limited to the removal of his assigned division of the Company’s operations or (ii) Mr. James not being assigned direct responsibility for the management and oversight of the international transcription and editing operations of the Company and its affiliates in the event that we, by acquisition, merger or otherwise, directly acquire ownership of our international transcription and editing operations; provided that any of the events described in clauses (i) and (ii) shall constitute good reason only if we fail to cure such event within 15 days after receipt from Mr. James of written notice of the event which constitutes good reason; provided, further, that “good reason” shall cease to exist for an event on the 30th day following the later of its occurrence or Mr. James’ knowledge thereof, unless he has given us written notice thereof prior to such date.

     Under the terms of our employment agreement with Mr. Piltz, he will be entitled to continuation of his then current base salary for a period of 6 months in the event he is terminated “without cause.”

     Under the terms of their respective employment agreements, each of Messrs. Sullivan and Clark will be entitled to the continuation of his then current base salary for a period of 12 months in the event he is terminated “without cause” or if he tenders his written resignation within 30 days following a substantial

and material diminution of his duties or a reduction in his base salary in excess of 10%, which diminution or reduction is not cured by us within 10 days of receiving his written resignation.

     In order to receive the severance payments described above, each named executive officer is required to execute and deliver a general release of claims against us.

     As used in their respective employment agreements, the term “cause” means the occurrence of any of the following: (1) such named executive officer’s refusal, willful failure or inability to perform (other than due to illness or disability) his employment duties or to follow the lawful directives of his superiors; (2) misconduct or gross negligence by such named executive officer in the course of employment; (3) conduct of such named executive officer involving fraud, embezzlement, theft or dishonesty in the course of employment; (4) a conviction of or the entry of a plea of guilty or nolo contendere to a crime involving moral turpitude or that otherwise could reasonably be expected to have an adverse effect on our operations, condition or reputation; (5) a material breach by such named executive officer of any agreement with or fiduciary duty owed to us or (6) alcohol abuse or use of controlled drugs other than in accordance with a physician’s prescription.

Applicable Restrictive Covenants

     Messrs. James, Piltz, Sullivan and Clark are bound by certain non-competition and non-solicitation covenants which extend for a period of one year following termination of their employment for any reason.

     Assuming a termination “without cause” had occurred on December 31, 2010 (the last business day of 2010), the payments to each of Messrs. Masanotti, James, Sullivan, Clark, Golio and Piltz, had an estimated value of:

		Salary
		Continuation				Accelerated Vesting
Name		($)				Option Grants(1) ($)				Total ($)
Peter Masanotti			500,000				633,889				1,133,889
Anthony D. James			300,000								300,000
Mark R. Sullivan			237,930				—				237,930
Michael Clark			275,000				—				275,000
Dominick Golio(2)			275,000				—				275,000
Kevin Piltz			140,000				—				140,000

Separation Arrangements with Former Executive Officer

Dominick Golio

     We entered into a formal Separation and Release Agreement with Mr. Golio, our former Chief Financial Officer, on April 22, 2011 (Golio Separation Agreement). Pursuant to the terms of the Golio Separation Agreement, Mr. Golio is entitled to receive continuation of his base salary as of the time of his termination for a period of 12 months

     In addition, the Golio Separation Agreement provides that Mr. Golio will be bound by the non-competition and non-solicitation covenants set forth in his employment agreement for a period of 12 months following his termination of employment. The Golio Separation Agreement also provides that Mr. Golio releases us from claims arising or occurring on or prior to the date of the Golio Separation Agreement.

Policies and Practices Related to Risk Management

     We have initiated an ongoing assessment of our compensation practices in light of the risks in our operations including, among other things, a review of management’s decision-making and policy-making structures and practices; the methodology used to define, update, and measure short-term and long-term objectives as part of our management incentive and sales force commission programs; the effectiveness and nature of communications within the Company and between management and our board of directors and various committees; and our compliance policies, practices, and programs. We believe that our compensation practices do not provide undue incentives, or are reasonably likely, to expose the Company to material risk.

Compensation Committee Interlocks and Insider Participation

     The current members of our Compensation Committee are Robert Aquilina (Chair), Frank Baker, and Peter Berger. Warren Pinckert also served on the Compensation Committee during 2010. In 2010, no member of our Compensation Committee was an officer or employee of ours. In addition, there are no Compensation Committee interlocks between us and other entities involving our executive officers and our board members who serve as executive officers of those other entities.

Compensation of Directors

     We currently do not pay Robert Aquilina, Frank Baker, and Peter Berger, nor did we pay Michael Seedman, each of whom is affiliated with our majority owner, MedQuist Holdings, any compensation for

their service on our board of directors. All directors are reimbursed for all reasonable expenses incurred by them in connection with their service on our board of directors. Our former independent directors, Messrs. Pinckert, Jastrem, O’Brien and Vogel, received the following compensation in 2010:

Annual Board Retainer		$110,000 to be paid in equal installments of:

	•		a non-refundable payment of $55,000 payable on February 15th of each year (for service period of February 15th to August 14th)
	•		a non-refundable payment of $55,000 payable on August 15th of each year (for service period of August 15th to February 14th)

Board Meeting Fees		$2,000 for meetings attended in person $1,000 for meetings attended by phone
Committee Chair Retainer		Audit Committee — $15,000
Committee Meeting Fees (All Committees)		$1,000 for meetings attended in person $500 for meetings attended by phone

     During 2010, our independent directors received the following compensation:

		Fees Earned or Paid in Cash
										Committee
										Chair				Committee
		Annual Board				Board Meeting				Retainers				Meeting Fees
Name		Retainer ($)				Fees ($)				($)				($)				Total ($)
Warren Pinckert			110,000				17,000				15,000				17,500				159,500
John Jastrem			110,000				17,000				—				16,500				143,500
Colin O’Brien			110,000				18,000				—				16,500				144,500
Andrew Vogel			110,000				18,000				—				17,500				145,500

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

Stock Ownership of our Directors, Executive Officers, and 5% Beneficial Owners

     The following table shows information known to us about beneficial ownership (as defined under the regulations of the SEC) of our common stock by:

	•		Each person we know to be the beneficial owner of at least five percent of our common stock;
	•		Each current director;
	•		Each person named in our Summary Compensation Table; and
	•		All current directors and executive officers as a group.

     The percentages of shares outstanding provided in the table below are based on 37,555,893 shares of common stock outstanding as of April 26, 2011. Beneficial ownership is determined in accordance with SEC rules and regulations and generally includes voting or investment power with respect to securities. Unless otherwise indicated, each person or entity named in the table below has sole voting and investment power, or shares voting and investment power with his or her spouse, with respect to all shares of stock listed as owned by that person. Shares issuable upon the exercise of options that are exercisable within 60 days of April 26, 2011 are included in the table below and are considered to be outstanding for the purpose of calculating the percentage of outstanding shares of our common stock held by the individual, but not for the purpose of calculating the percentage of outstanding shares held by any other individual. The address of our directors and executive officers is c/o MedQuist Inc., 9009 Carothers Parkway, Suite C-2, Franklin, TN 37067.

		Number of Shares of				Percent of
		Common Stock				Shares
Name of Beneficial Owner		Beneficially Owned				Outstanding
MedQuist Holdings Inc. (1)			36,324,647				96.7	%
9009 Carothers Parkway, Suite C-2, Franklin, TN 37067
Directors, Named Executive Officers and Former Named Executive Officers
Robert Aquilina (1)			36,324,647				96.7	%
Frank Baker (1)			36,324,647				96.7	%
Peter E. Berger (1)			36,324,647				96.7	%
Peter Masanotti (2)			246,458				—
Mark R. Sullivan (3)			2,566				*
Michael Clark (4)			29,000				*
Dominick Golio(5)			—				—
Kevin Piltz			—				—
Anthony D. James			—				—
All current directors and executive officers as a group (8 persons) (1) (2) (3) (4) (6)							97.5	%

Securities Authorized for Issuance Under Equity Compensation Plans

     The following table sets forth, as of December 31, 2010, information concerning equity compensation plans under which our securities are authorized for issuance. The table does not reflect grants, awards, exercises, terminations or expirations since that date. All share amounts and exercise prices have been adjusted to reflect stock splits that occurred after the date on which any particular underlying plan was adopted, to the extent applicable.

(A)

(B)

(C)

Number of Securities

Remaining Available

for Future Issuance

under Equity

Number of Securities to

Weighted Average

Compensation Plans

be Issued Upon Exercise

Exercise Price of

(excluding securities

of Outstanding Options,

Outstanding Options,

reflected

Plan Category

Warrants and Rights

Warrants and Rights

in column (A))

Plans Approved by Shareholders

1,002,000

$

17.39

1,015,841

(1)

Plans Not Approved by Shareholders

—

—

—

Total

1,002,000

$

17.39

1,015,841

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

Related Party Transactions

Majority Shareholder

     On August 6, 2008, CBay acquired approximately 69.5% of our outstanding common stock from our former majority shareholder, Philips. The transaction was more fully described in our Current Report on Form 8-K filed with the SEC on August 8, 2009.

Related Party Transaction Policy

     From time to time, we enter into transactions in the normal course of business with related parties. Prior to their March 25, 2011 resignations, the Audit Committee of our board of directors consisted of four independent directors (Messrs. Jastrem, O’Brien, Vogel and Pinckert). The Audit Committee, consisting of independent directors, was charged with the responsibility of approving or ratifying all related party transactions. To ensure that the terms of the related party transactions were not less favorable than what would be obtained in an arm’s-length transaction, the material terms and conditions of the related party agreements described below were reviewed and approved by the Audit Committee prior to the March 25, 2011 resignations of the independent directors serving on our Audit Committee pursuant to our Related Party Transaction Policy and at the time of the review and approval of such related party transactions, the Audit Committee was comprised solely of independent directors, none of

whom had an interest in any of the related party transactions. In any situation where the Audit Committee saw fit to do so, any related party transaction, would have been presented to disinterested members of our board of directors for approval or ratification. All of the agreements with CBay Inc. and its affiliates described below were reviewed and approved by our Audit Committee prior to the March 25, 2011 resignations of the independent directors serving on our Audit Committee.

MedQuist Holdings had an approximately 69.5% ownership interest in us at December 31, 2010.

     We have an agreement with a wholly-owned subsidiary of MedQuist Holdings, CBay Systems & Services, Inc. (CBay Services), under which we outsource medical transcription services. We incurred expenses of $34.04 million, for the year ended December 31, 2010. We recorded other expense of $.054 million in 2010 recorded in research and development.

     We also have a subcontracting agreement (Subcontracting Agreement) with CBay Services, pursuant to which CBay Services subcontracts medical transcription, editing and related services to us. For the year ended December 31, 2010, we recorded revenue of $2.29 million.

     We have a Management Services Agreement with CBay Inc, pursuant to which certain senior executives and directors of CBay Inc. provide certain advisory and consulting services. The Management Services Agreement provides that, in consideration of the management services rendered by CBay Inc. to us since July 1, 2009 we pay CBay Inc. a quarterly services fee equal to $350,000, payable in arrears. For the year ended December 31, 2010, we incurred $1.4 million in services expenses with CBay Inc.

     Payment of fee to S A C Private Capital Group, LLC in connection with Spheris acquisition

     On May 4, 2010, the Audit Committee of our board of directors approved the payment of and we expensed a $1.5 million success-based fee to S A C Private Capital Group, LLC (SAC) in connection with work performed on the Spheris acquisition. SAC owns a majority interest in CBaySystems Holdings Limited, the majority owner of CBay Inc.

Indemnification Agreements

     On August 23, 2007, we entered into indemnification agreements with Messrs. Sullivan and Clark (Officer Indemnification Agreements). Each indemnification agreement is substantially similar and provides, among other things, that to the extent permitted by New Jersey law, we will indemnify the executive officer against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in conjunction with any suit in which he or she is a party or otherwise involved as a result of his or her service as an executive officer. Each of these indemnification agreements was amended on August 19, 2008 to require us to obtain and maintain insurance policies providing our executive officers with coverage for losses in connection with their acts or omissions or to ensure our performance of our indemnification obligations under the indemnification agreements.

     On February 21, 2008, we entered into an indemnification agreement with Mr. Pinckert. The indemnification agreement is substantially similar to the Officer Indemnification Agreements and provides, among other things, that to the extent permitted by New Jersey law, we will indemnify Mr. Pinckert against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with any suit in which he is a party or otherwise involved as a result of his service as a member of our board of directors.

     On August 19, 2008, we entered into indemnification agreements with Messrs. Aquilina, Baker, Berger and Seedman. Each indemnification agreement is substantially similar to the Officer Indemnification Agreements and provides, among other things, that to the extent permitted by New Jersey law, we will indemnify each of Messrs. Aquilina, Baker, Berger and Seedman against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with any suit in which he is a party or otherwise involved as a result of his service as a member of our board of directors.

     On November 21, 2008, we entered into indemnification agreements with Messrs. Jastrem, Masanotti, O’Brien and Vogel. Each indemnification agreement is substantially similar to the Officer Indemnification Agreements and provides, among other things, that to the extent permitted by New Jersey law, we will indemnify each of Messrs. Jastrem, Masanotti, O’Brien and Vogel against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with any suit in which he is a party or otherwise involved as a result of his service as a member of our board of directors, or as our President and Chief Executive Officer, as applicable.

Independence of Directors

     For information regarding the independence of our directors, please see the discussion under Item 10, below the heading “Independence of Directors,” which discussion is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

     The Audit Committee of our board of directors is responsible for the appointment, compensation, oversight and replacement, if necessary, of our independent registered public accounting firm. In accordance with the charter of the Audit Committee, the Audit Committee must approve, in advance of the service, all audit, internal control-related and permissible non-audit services provided by our independent registered public accounting firm, subject to a de minimis exception for non-audit services. In its review of non-audit service fees, the Audit Committee considers, among other things, the possible effect of the performance of such services on the independence of our independent registered public accounting firm. Our independent registered public accounting firm may not be retained to perform any of the non-audit services specified in Section 10A(g) of the Exchange Act.

     All services provided by KPMG LLP, our independent registered accounting firm, for the years ended December 31, 2010 and 2009 were preapproved by the Audit Committee.

Fees Paid to the Principal Accountant — 2010 and 2009

     The following table sets forth the aggregate fees billed to us for the years ended December 31, 2010 and 2009 by KPMG LLP (in thousands):

Fees		2010				2009
Audit Fees (1)		$	1,508			$	1,279
Audit-Related Fees(2)			—				185
Tax Fees (3)			17				96
All Other Fees			—				—
Total Fees		$	1,525			$	1,560

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) Documents filed as part of this report:

     (3) Exhibits. See (b) below.

(b) Exhibits:

No.		Description
3.1(1)		Certificate of Incorporation of MedQuist Inc. (as amended)
3.2(6)		Second Amended and Restated By-Laws, as amended, of MedQuist Inc.
4.1(1)		Specimen Stock Certificate
10.1*(1)		1992 Stock Option Plan of MedQuist Inc., as amended
10.2*(1)		Nonstatutory Stock Option Plan for Non-Employee Directors of MedQuist Inc.
10.3*(1)		MedQuist Inc. 2002 Stock Option Plan
10.4*(1)		Form of Award Agreement under the MedQuist Inc. 2002 Stock Option Plan
10.5*(1)		1996 Employee Stock Purchase Plan
10.6*(1)		MedQuist Inc. Executive Deferred Compensation Plan
10.7*(1)		Letter Agreement, dated as of April 21, 2005, between MedQuist Inc. and Michael Clark
10.8*(1)		Letter Agreement, dated as of April 21, 2005, between MedQuist Inc. and Mark Sullivan
10.10*(1)		Letter Agreement, dated as of November 10, 2006, by and between MedQuist Inc. and James Brennan
10.11(1)		Licensing Agreement, dated as of May 22, 2000, between MedQuist Inc. and Philips Speech Processing GmbH
10.11.1(1)		Amendment No. 1 to Licensing Agreement, dated as of January 1, 2002, between MedQuist Inc. and Philips Speech Processing GmbH
10.11.2#(1)		Amendment No. 2 to Licensing Agreement, dated as of December 10, 2002, between MedQuist Inc. and Philips Speech Processing GmbH
10.11.3#(1)		Amendment No. 3 to Licensing Agreement, dated as of August 10, 2003, between MedQuist Inc. and Philips Speech Processing GmbH
10.11.4#(1)		Amendment No. 4 to Licensing Agreement, dated as of September 1, 2004, between MedQuist Inc. and Philips Speech Processing GmbH
10.11.5#(1)		Amendment No. 5 to Licensing Agreement, dated as of December 30, 2005, between MedQuist Transcriptions, Ltd. and Philips Speech Recognition Systems GmbH f/k/a Philips Speech Processing GmbH

No.		Description
10.11.6#(1)		Amendment No. 6 to Licensing Agreement, dated as of February 13, 2007, between MedQuist Inc. and Philips Speech Recognition Systems GmbH f/k/a Philips Speech Processing GmbH
10.11.7(17)		Amendment No. 7 to Licensing Agreement, dated as of November 10, 2009, between MedQuist Inc. and Nuance Communications, Inc. as the successor-in-interest to Philips Speech Recognition Systems GmbH
10.12##(17)		Third Amended and Restated OEM Supply Agreement dated November 10, 2009, between MedQuist Inc. and Nuance Communications, Inc. as the successor-in-interest to Philips Speech Recognition Systems GmbH
10.13*(1)		MedQuist Inc. Board of Directors Deferred Compensation Plan
10.14*(2)		Form of Management Indemnification Agreement by and between MedQuist Inc. and Certain Officers
10.14.1*(7)		First Amendment to the Form of Management Indemnification Agreement by and between MedQuist Inc. and Certain Officers
10.15*(4)		Indemnification Agreement, dated as of February 21, 2008 between MedQuist Inc. and Warren Pinckert
10.16*(8)		Employment Agreement by and between Peter Masanotti and MedQuist Inc., dated September 3, 2008
10.17#(9)		Transcription Services Agreement by and between MedQuist Transcriptions, Ltd. and CBay Systems & Services, Inc. dated April 3, 2009
10.18*(10)		Indemnification Agreement dated November 21, 2008 between MedQuist Inc. and Peter Masanotti
10.19*(11)		Amended and Restated Stock Option Agreement by and between Peter Masanotti and MedQuist Inc., dated March 2, 2009
10.21*(12)		Employment Agreement by and between Dominick Golio and MedQuist Inc. dated April 9, 2009
10.22*(9)		Employment Agreement by and between Kevin Piltz and MedQuist Inc. dated May 18, 2009
10.23(9)		Settlement and License Agreement by and between Anthurium Solutions, Inc. and MedQuist Inc. dated June 19, 2009
10.24*(13)		MedQuist Inc. Long-Term Incentive Plan adopted on August 27, 2009
10.25(13)		Credit Agreement by and among MedQuist Inc. and its subsidiaries, and Wells Fargo Foothill, LLC as the arranger and administrative agent and lender dated August 31, 2009
10.26(14)		Services Agreement by and between MedQuist Inc. and CBay Inc. dated September 19, 2009
10.27##(17)		Licensing Agreement by and between Nuance Communications, Inc. and MedQuist Inc. dated November 10, 2009
10.28(15)		Transcription Services Subcontracting Agreement by and between MedQuist Inc. and CBay Systems & Services, Inc. dated March 31, 2009
10.29(19)		Credit Agreement dated as April 22, 2010 among MedQuist Transcriptions, Ltd. as Borrower, MedQuist Inc. as Holdings, the Lenders and L/C Issuers party thereto, and General Electric Capital Corporation as Administrative Agent and Collateral Agent, CapitalSource Bank as Syndication Agent, and Fifth Third Bank as Documentation Agent.

No.		Description
10.30(20)		MedQuist Transcriptions, Ltd. Subordinated Promissory Note dated April 22, 2010
10.31##(20)		Sales & Services Agreement dated March 9, 2010 between MedQuist, Inc. and CBay Systems & Services, Inc.
10.32(21)		Employment Agreement between Anthony D. James and MedQuist, Inc. for the position of Co-Chief Operating Officer dated June 24, 2010
10.33##(24)		Amendment No. 1 to the Sales and Services Agreement, dated July 26, 2010 between MedQuist, Inc. and CBay Systems & Services, Inc.
10.34##(24)		Amendment No. 1 to the Subcontracting Agreement dated July 26, 2010, between MedQuist, Inc. and CBay Systems & Services, Inc.
10.35(22)		Settlement Agreement and Release dated August 12, 2010 between MedQuist Inc. and Kaiser Foundation Health Plan, Inc.
10.36(24)		First Amendment to Norcross, Georgia Office Lease Agreement dated as of March 1, 2009
10.37(24)		Second Amendment to Norcross, Georgia Office Lease Agreement dated as of August 1, 2009
10.38(23)		Senior Subordinated Note Purchase Agreement, dated September 30, 2010, between CBay Inc., CBay, the Company, MedQuist Transcriptions, Ltd., Blackrock Kelso Capital Corporation, PennantPark Investment Corporation, Citibank, N.A. and THL Credit, Inc. as Purchasers.
10.39(23)		Credit Agreement, dated October 1, 2010, between CBay Inc., the Company and MedQuist Transcriptions, Ltd., CBay, the lenders and L/C issuers, General Electric Capital Corporation, as administrative agent and collateral agent
10.40(25)		Appointed Anthony D. James as Chief Financial Officer of MedQuist Inc., dated November 22, 2010
10.41(26)		Licensing Agreement of Trade Name, dated as of Nov. 23, 2010, between MedQuist Inc. and CBaySystems Holdings Limited
10.42.1		Office Lease, dated June 2006, between Ford Motor Land Development Corporation and Spheris Operations Inc.
10.42.2		Amendment to Office Lease Agreement, dated March 27, 2009, between Carothers Office Acquisition LLC and Spheris Operations, Inc.
10.42.3		Assignment, Assumption and Agreement to Relinquish Office Space and Amendment to Office Lease Agreement, dated April 22, 2010 between Carothers Office Acquisition LLC and MedQuist Transcriptions, Ltd.
10.43(24)		First Amendment to Lease Agreement, dated March 1, 2009, by and between Atlanta Lakeside Real Estate, L.P. and MedQuist Transcriptions, Ltd.
10.44(24)		Second Amendment to Lease Agreement, effective August 1, 2009, by and between Atlanta Lakeside Real Estate, L.P. and MedQuist Transcriptions, Ltd.
21(1)		Subsidiaries of MedQuist Inc.
23		Consent of KPMG LLP
24		Power of Attorney (included on the signature page hereto)

No.		Description
31.1		Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

     Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX

Exhibit		Description
31.1		Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002